Evidence map›Paper›PMID 33494963›Full record

ArticleVaccine2021

Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing.

DeAnna J Friedman-Klabanoff, Andrea A Berry, Mark A Travassos, Catherine Cox, Yingjun Zhou, Annie X Mo, Effie Y H Nomicos, Gregory A Deye, Marcela F Pasetti, Matthew B Laurens

Open access · greenAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Historical Advances in Clinical Trial Design and Expanding Representation as the New Frontier for Innovation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Malaria Vaccines: Progress to Date.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023
    Review
  8. Article
  9. Current approaches to malaria vaccines.Current opinion in microbiology · 2022
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Restricted valency (NPNA)NPJ vaccines · 2022
    Article
  15. Novel malaria vaccines.Human vaccines & immunotherapeutics · 2021
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

DeAnna J Friedman-KlabanoffCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Andrea A BerryCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Mark A TravassosCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Catherine CoxThe Emmes Company, LLC, Rockville, MD, USA.
Yingjun ZhouThe Emmes Company, LLC, Rockville, MD, USA.
Annie X MoParasitology and International Programs Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Effie Y H NomicosParasitology and International Programs Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Gregory A DeyeParasitology and International Programs Branch, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Marcela F PasettiCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA.
Matthew B LaurensCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: mlaurens@som.umaryland.edu.
University of Maryland, Baltimore · USNational Institutes of Health · USEmmes (United States) · US

Funding

FELLOWSHIP TRAINING PROGRAM IN VACCINOLOGYT32AI007524 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1997 to 2026
$6.4M
NIAID NIH HHS HHSN272201200005CNIAID NIH HHS HHSN272201300022CNIAID NIH HHS HHSN272201300022INIAID NIH HHS HHSN272201800009CNIAID NIH HHS T32 AI007524
6 · The paper itself

Abstract

Plasmodium falciparum circumsporozoite protein (CSP) is a major sporozoite surface protein and a key target of pre-erythrocytic malaria subunit vaccines. A full-length recombinant CSP (rCSP) based strategy could be advantageous, as this antigen includes a region critical to sporozoite cell attachment and hepatocyte invasion. The adjuvant Glucopyranosyl Lipid A-liposome Quillaja saponaria 21 (GLA-LSQ) functions as a TLR4 agonist, promotes antigen-specific T

Indexed as

Malaria, FalciparumMalaria VaccinesAnimalsAntibodies, ProtozoanAntibody FormationHumansPlasmodium falciparumProtozoan ProteinsVaccines, SyntheticAntibodies, ProtozoanMalaria VaccinesProtozoan ProteinsVaccines, SyntheticCircumsporozoite proteinMalariaMalaria vaccinePlasmodium falciparum

Identifiers

PMID33494963
PMCPMC9014455
OpenAlexW3125872398

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.